Quarter Comparison
Revenue
Operating Income
Gross Margin
Net Margin
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 tm2622246d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., August 6, 2026 — CytoSorbents Corporation (NASDAQ: CTSO
EX-99.1 2 tm2622246d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., August 6, 2026 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the second quarter ended June 30, 2026, recent business highlights, and provides a regulatory update. Second Quarter 2026 Financial Results · Revenue was $9.6 million, unchanged from a year ago. · Gross margin improved to 73% in the quarter, up sequentially from 69% in Q1 2026 and from 71% a year ago. · Operating loss improved by 27% to $2.6 million versus $3.6 million in Q2 2025. · Net loss was $4.4 million or $0.07 per share...
Source
Exhibit EX-99.1
0001104659-26-092039
Filed August 6, 2026 at 8:19 PM UTC. The figures above are from the audited statements, not from this release.